Teva pharmaceuticals v. sandoz: Availability of generic glatiramer acetate and the impact to patent litigation claim construction

Abstract

In the upcoming case of Teva Pharmaceuticals v. Sandoz, the U.S. Supreme Court will address how much deference the appellate court should afford to a trial court's claim construction ruling. The effect of this decision will be far-reaching, as how claims are construed can determine whether a patent is infringed or not infringed, valid or invalid.